Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: London, Macmillan Journals Ltd.
    • Subject Terms:
      Cardiac Glycosides/*pharmacokinetics ; Cyclooxygenase Inhibitors/*pharmacokinetics ; Digoxin/*pharmacokinetics ; Pyridines/*pharmacokinetics ; Sulfones/*pharmacokinetics; Adult ; Area Under Curve ; Cardiac Glycosides/administration & dosage ; Cyclooxygenase Inhibitors/administration & dosage ; Digoxin/administration & dosage ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Interactions ; Epidemiologic Methods ; Etoricoxib ; Female ; Humans ; Male ; Metabolic Clearance Rate ; Pyridines/administration & dosage ; Sulfones/administration & dosage ; Young Adult
    • Abstract:
      Aims: Digoxin is a commonly prescribed cardiac glycoside with a narrow therapeutic index. The aim was to investigate whether the cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug etoricoxib affects the steady-state pharmacokinetics of digoxin.
      Methods: This was a double-blind, randomized, placebo-controlled, two-period cross-over study. In each period, 14 healthy volunteers ranging in age from 21 to 35 years received oral digoxin 0.25 mg daily and were randomized to either etoricoxib 120 mg or matching placebo tablets once daily for 10 days. Trough digoxin plasma concentrations were analysed by linear regression to examine digoxin accumulation over time.
      Results: The geometric mean ratios (etoricoxib/placebo) for AUC(0-24h), C(max) and urinary excretion were 1.06 (90% confidence interval 0.97, 1.17), 1.33 (1.21, 1.46) and 1.10 (1.00, 1.20), respectively. The median (range) for digoxin T(max) (h) values with etoricoxib and placebo were 0.5 (0.5, 1.5) and 1.0 (0.5, 1.5), respectively. Steady-state digoxin plasma concentrations were achieved by day 7 in each treatment period. No serious adverse experiences were reported.
      Conclusions: Although etoricoxib 120 mg did produce an approximately 33% increase in digoxin C(max), this increase does not appear to be clinically meaningful, as cardiotoxicity with digoxin has been associated with elevations in steady-state rather than peak concentrations. From these results, it appears that etoricoxib does not cause any changes in digoxin steady-state pharmacokinetics that would necessitate a dose adjustment.
    • References:
      Eur J Clin Pharmacol. 1998 Jun;54(4):355-7. (PMID: 9696964)
      Br J Clin Pharmacol. 1997 May;43(5):475-80. (PMID: 9159562)
      Am Heart J. 2006 Aug;152(2):237-45. (PMID: 16875903)
      Lancet. 2006 Nov 18;368(9549):1771-81. (PMID: 17113426)
      Lancet. 2007 Feb 10;369(9560):465-73. (PMID: 17292766)
      J Clin Pharmacol. 2007 Dec;47(12):1521-31. (PMID: 17925592)
      Ann Intern Med. 2000 Jul 4;133(1):1-9. (PMID: 10877734)
      J Clin Pharmacol. 2001 Jan;41(1):107-12. (PMID: 11144988)
      Ther Drug Monit. 2000 Feb;22(1):137-40. (PMID: 10688277)
      Am J Cardiol. 2002 Mar 21;89(6A):10D-17D. (PMID: 11909556)
      Curr Med Res Opin. 2002;18(2):82-91. (PMID: 12017215)
      Clin Pharmacol Ther. 2002 Jul;72(1):50-61. (PMID: 12152004)
      Aliment Pharmacol Ther. 2003 Jan;17(2):201-10. (PMID: 12534404)
      J Clin Pharmacol. 2003 Jun;43(6):573-85. (PMID: 12817520)
      Am J Gastroenterol. 2003 Aug;98(8):1725-33. (PMID: 12907325)
      Clin Ther. 2004 Jan;26(1):70-83. (PMID: 14996519)
      Drugs Today (Barc). 2004 May;40(5):395-414. (PMID: 15319795)
      Br J Pharmacol. 1976 May;57(1):23-7. (PMID: 1276538)
      Stat Bull Metrop Life Found. 1983 Jan-Jun;64(1):3-9. (PMID: 6623350)
      Clin Pharmacokinet. 1988 Oct;15(4):227-44. (PMID: 3056649)
      Dig Dis Sci. 1995 Jun;40(6):1345-50. (PMID: 7781458)
      Clin Pharmacokinet. 1995;29 Suppl 2:92-7. (PMID: 8620677)
      Arch Intern Med. 1998 Dec 7-21;158(22):2444-9. (PMID: 9855382)
    • Accession Number:
      0 (Cardiac Glycosides)
      0 (Cyclooxygenase Inhibitors)
      0 (Pyridines)
      0 (Sulfones)
      73K4184T59 (Digoxin)
      WRX4NFY03R (Etoricoxib)
    • Publication Date:
      Date Created: 20081001 Date Completed: 20090331 Latest Revision: 20181201
    • Publication Date:
      20240829
    • Accession Number:
      PMC2675761
    • Accession Number:
      10.1111/j.1365-2125.2008.03285.x
    • Accession Number:
      18823299